Back to top
more

Myriad Genetics: (MYGN)

(Delayed Data from NSDQ)

 Add to portfolio

$34.21 USD

34.21
1,382,483

+0.09 (0.26%)

Updated Feb 12, 2016 03:59 PM ET

Volume: 1,382,483

Open: $34.51

Prior Close: $34.12

Is MYGN a
Buy, Hold or Sell?

See its Zacks Rank in our free stock analysis report.

Get Free Report for MYGN

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Zacks Style Score A
Growth Score A
Value Score A
Momentum Score A
Income Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The three scores are based on the trading styles of Growth, Value, and Momentum.

Growth Score A
Value Score A
Momentum Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1 Strong Buy 25.71%
2 Buy 18.12%
3 Hold 9.91%
4 Sell 5.49%
5 Strong Sell 2.29%
S&P 500 9.79%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The way to access to the Zacks Rank

Balance Sheet

The Zacks Scorecard is a complimentary set of indicators to use alongside the Zacks Rank. It allows the investor to better focus on the stocks that are the best fit for his or her personal investment style.

We produce five unique ratings, including the Zacks Style Score, which combines the individual style scores into 1 rating:

Growth Score A
Value Score A
Momentum Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a score of an A or a B in your personal trading style.

Zacks Scorecard Education - Learn more about the Zacks Scorecard

Save at Trade

Fiscal Year End for MYRIAD GENETICS falls in the month of June.

All items in Millions except Per Share data.

6/30/2015 6/30/2014 6/30/2013 6/30/2012 6/30/2011
Assets          
Cash & Equivalents 145 186 372 341 346
Receivables 88 85 98 63 51
Notes Receivable 0 0 0 0 0
Inventories 25 24 5 12 6
Other Current Assets 26 27 9 7 15
Total Current Assets 284 322 484 422 418
Net Property & Equipment 67 35 28 24 23
Investments & Advances 41 84 159 114 71
Other Non-Current Assets 0 0 22 19 0
Deferred Charges 0 3 29 31 26
Intangibles 370 374 70 73 73
Deposits & Other Assets 5 5 13 8 0
Total Assets 766 824 804 691 611
Liabilities & Shareholders Equity 6/30/2015 6/30/2014 6/30/2013 6/30/2012 6/30/2011
Notes Payable 0 0 0 0 0
Accounts Payable 21 23 18 10 11
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 46 56 44 33 22
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 1 2 2 1
Total Current Liabilities 69 81 65 45 34
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 0
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 35 24 11 10 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 104 105 75 55 44
Shareholders Equity 6/30/2015 6/30/2014 6/30/2013 6/30/2012 6/30/2011
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 745 718 697 648 604
Retained Earnings -77 2 31 -13 -39
Other Equity -7 -2 -0 -0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 662 719 729 636 567
Total Liabilities & Shareholder's Equity 766 824 804 691 611
Total Common Equity 662 719 729 636 567
Shares Outstanding 69.40 74.80 79.60 84.80 85.70
Book Value Per Share 9.54 9.61 9.15 7.50 6.61

Fiscal Year End for MYRIAD GENETICS falls in the month of June.

All items in Millions except Per Share data.

12/31/2015 9/30/2015 6/30/2015 3/31/2015 12/31/2014
Assets          
Cash & Equivalents 219 155 145 134 187
Receivables 89 85 88 95 87
Notes Receivable 0 0 0 0 0
Inventories 29 34 25 29 20
Other Current Assets 38 33 26 23 26
Total Current Assets 376 307 284 282 320
Net Property & Equipment 62 65 67 69 46
Investments & Advances 66 43 41 41 42
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 363 367 370 381 368
Deposits & Other Assets 5 5 5 5 5
Total Assets 872 787 766 779 782
Liabilities & Shareholders Equity 12/31/2015 9/30/2015 6/30/2015 3/31/2015 12/31/2014
Notes Payable 0 0 0 0 0
Accounts Payable 17 16 21 18 17
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 48 42 46 48 41
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 2 1 2 1 2
Total Current Liabilities 66 59 69 67 60
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 7 0 10 2
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 35 35 33 25
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 101 100 104 110 88
Shareholders Equity 12/31/2015 9/30/2015 6/30/2015 3/31/2015 12/31/2014
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 1
Capital Surplus 848 772 745 738 735
Retained Earnings -69 -79 -77 -62 -37
Other Equity -9 -7 -7 -8 -4
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 771 687 662 669 694
Total Liabilities & Shareholder's Equity 872 787 766 779 782
Total Common Equity 771 687 662 669 694
Shares Outstanding 69.70 69.30 69.40 71.10 72.90
Book Value Per Share 11.06 9.91 9.54 9.41 9.52